Success Metrics

Clinical Success Rate
33.3%

Based on 1 completed trials

Completion Rate
33%(1/3)
Active Trials
1(25%)
Results Posted
200%(2 trials)
Terminated
2(50%)

Phase Distribution

Ph phase_1
1
25%
Ph phase_3
2
50%
Ph not_applicable
1
25%

Phase Distribution

1

Early Stage

0

Mid Stage

2

Late Stage

Phase Distribution4 total trials
Phase 1Safety & dosage
1(25.0%)
Phase 3Large-scale testing
2(50.0%)
N/ANon-phased studies
1(25.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

33.3%

1 of 3 finished

Non-Completion Rate

66.7%

2 ended early

Currently Active

1

trials recruiting

Total Trials

4

all time

Status Distribution
Active(1)
Completed(1)
Terminated(2)

Detailed Status

Terminated2
Active, not recruiting1
Completed1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
1
Success Rate
33.3%
Most Advanced
Phase 3

Trials by Phase

Phase 11 (25.0%)
Phase 32 (50.0%)
N/A1 (25.0%)

Trials by Status

active_not_recruiting125%
terminated250%
completed125%

Recent Activity

1 active trials
Showing 4 of 4
active_not_recruitingphase_1

Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants With Solid Tumors

NCT03313778
terminatedphase_3

A Study to Evaluate the Efficacy and Safety of Pimodivir in Combination With the Standard-of-Care Treatment in Adolescent, Adult, and Elderly Non-Hospitalized Participants With Influenza A Infection Who Are at Risk of Developing Complications

NCT03381196
terminatedphase_3

A Study to Evaluate the Efficacy and Safety of Pimodivir in Combination With the Standard-of-Care Treatment in Adolescent, Adult, and Elderly Hospitalized Participants With Influenza A Infection

NCT03376321
completednot_applicable

Study Evaluating CERAMENT™|G in Open Diaphyseal Tibial Fractures

NCT02820363

Clinical Trials (4)

Showing 4 of 4 trials
NCT03313778Phase 1

Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants With Solid Tumors

Active Not Recruiting
NCT03381196Phase 3

A Study to Evaluate the Efficacy and Safety of Pimodivir in Combination With the Standard-of-Care Treatment in Adolescent, Adult, and Elderly Non-Hospitalized Participants With Influenza A Infection Who Are at Risk of Developing Complications

Terminated
NCT03376321Phase 3

A Study to Evaluate the Efficacy and Safety of Pimodivir in Combination With the Standard-of-Care Treatment in Adolescent, Adult, and Elderly Hospitalized Participants With Influenza A Infection

Terminated
NCT02820363Not Applicable

Study Evaluating CERAMENT™|G in Open Diaphyseal Tibial Fractures

Completed

All 4 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
4